Possibility for Dose Optimization of Pazopanib from Its Plasma Concentration in Japanese Patients with Cancer
- 1 May 2020
- journal article
- research article
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 43 (5) , 762-766
Abstract
The currently approved dose of pazopanib (800 mg) is being re-examined owing to its adverse effects. The aim of this study was to evaluate the relationships among starting or maintenance doses of pazopanib, estimated pazopanib Cmin, and other clinical factors, including albumin and α-1 acid glycoprotein levels, in soft-tissue sarcoma and renal cell carcinoma. We also determined whether therapeutic drug monitoring of pazopanib concentrations may be used to improve its therapeutic efficacy and prevent adverse effects. Forty patients who received pazopanib for renal cancer or soft-tissue sarcoma at the Hokkaido Cancer Center were evaluated prospectively. Cmin for pazopanib was calculated based on the measured values from the plasma samples. The efficacy and time to treatment failure were then assessed. The pazopanib maintenance doses were 200 mg (n = 4), 400 mg (n = 34), 600 mg (n = 4), and 800 mg (n = 1). Most patients (65%) who received a 400 mg dose had an effective pazopanib concentration (≧20 µg/mL), whereas 35% of patients who received the 400 mg dose had ineffective concentrations (<20 µg/mL). Logistic regression analysis revealed that only the albumin level was significantly associated with effective pazopanib concentrations (odds ratio: 1.37, p = 0.0234). In conclusion, a dose of 400 mg had been effective and well tolerated in more than half of patients in this study. However, therapeutic drug monitoring is necessary during pazopanib therapy.Keywords
This publication has 9 references indexed in Scilit:
- Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding siteInvestigational New Drugs, 2015
- Development and Validation of an HPLC-UV Method for Pazopanib Quantification in Human Plasma and Application to Patients With Cancer in Routine Clinical PracticeTherapeutic Drug Monitoring, 2015
- Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinomaBritish Journal of Cancer, 2014
- Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumorsCancer Chemotherapy and Pharmacology, 2013
- HPLC–DAD protein kinase inhibitor analysis in human serumJournal of Chromatography B, 2012
- An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid TumorsClinical Pharmacology & Therapeutics, 2010
- A Therapeutic Drug Monitoring Algorithm for Refining the Imatinib Trough Level Obtained at Different Sampling TimesTherapeutic Drug Monitoring, 2009
- Phase I Trial of Pazopanib in Patients with Advanced CancerClinical Cancer Research, 2009
- Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activityMolecular Cancer Therapeutics, 2007